Literature DB >> 29145775

Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).

Abbas Ali Tasneem1, Nasir Hassan Luck2, Zain Majid3.   

Abstract

Introduction To determine the factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Methodology All patients aged >18 years and having a fatty liver on abdominal ultrasound (US), presenting from January 2011 to January 2017, were included. A liver biopsy was performed on all the patients. Results Of 96 patients undergoing liver biopsy for non-alcoholic fatty liver disease (NAFLD), 76 (79.2%) were men. On liver US, diffuse fatty liver (DFL) was noted in 68 (70.8%) patients. Liver biopsy showed non-alcoholic steatohepatitis (NASH) in 78 (81.3%) patients. Factors associated with NASH were male gender, body mass index (BMI) > 27 kg/m2, DFL and raised alanine aminotransferase (ALT). A GULAB score (based on gender, US liver findings, lipid (fasting) levels, ALT level and BMI) of ≥5 predicted NASH with 82.05% sensitivity. Factors associated with advanced fibrosis in NAFLD were age >40 years, diabetes mellitus, AST/ALT ratio > 1 and raised GGT. Conclusion NASH is common in patients with male gender, high BMI, DFL on liver US, raised ALT and GULAB score ≥5.

Entities:  

Keywords:  Disease prevention; NAFLD; NASH; Public health; diagnosis

Mesh:

Substances:

Year:  2017        PMID: 29145775     DOI: 10.1177/0049475517742261

Source DB:  PubMed          Journal:  Trop Doct        ISSN: 0049-4755            Impact factor:   0.731


  8 in total

1.  Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B.

Authors:  Duo-Duo Lv; You-Juan Wang; Meng-Lan Wang; En-Qiang Chen; Ya-Chao Tao; Dong-Mei Zhang; Hong Tang
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

2.  Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy.

Authors:  Zhipeng Xu; Wenxin Hu; Bin Wang; Ting Xu; Jianning Wang; Dan Wei
Journal:  Yonsei Med J       Date:  2022-07       Impact factor: 3.052

3.  The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.

Authors:  Dong Wang; Yuhuan Luo; Xiaoxin Wang; David J Orlicky; Komuraiah Myakala; Pengyuan Yang; Moshe Levi
Journal:  Int J Mol Sci       Date:  2018-01-03       Impact factor: 5.923

4.  Can simple Non-Invasive Fibrosis Models Determine Prognostic Indicators (Fibrosis and Treatment Response) of Primary Biliary Cholangitis?

Authors:  Suleyman Sayar; Pinar Gokcen; Huseyin Aykut; Gupse Adali; Hamdi Levent Doganay; Kamil Ozdil
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-09-24

5.  Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States.

Authors:  Leonardo Ruiz-Casas; Gabriel Pedra; Anum Shaikh; Bethany Franks; Harpal Dhillon; João Diogo da Rocha Fernandes; Kamal Kant Mangla; Margarida Augusto; Jörn M Schattenberg; Manuel Romero-Gómez
Journal:  Medicine (Baltimore)       Date:  2021-12-17       Impact factor: 1.817

6.  Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver.

Authors:  Amir Hajighasem; Parvin Farzanegi; Zohreh Mazaheri; Marjan Naghizadeh; Ghoncheh Salehi
Journal:  PeerJ       Date:  2018-09-10       Impact factor: 2.984

7.  Association between serum uric acid and nonalcoholic fatty liver disease in community patients with type 2 diabetes mellitus.

Authors:  Linxin Xu; Ting Li; Jianhong Yin; Gang Lin; Yali Xu; Yi Ren; Yan Wang; Jing Yang; Liming Chen
Journal:  PeerJ       Date:  2019-08-26       Impact factor: 2.984

Review 8.  Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).

Authors:  Madhangi Parameswaran; Hamzah A Hasan; Jafor Sadeque; Sharan Jhaveri; Chaithanya Avanthika; Abimbola E Arisoyin; Maulik B Dhanani; Swaroopa M Rath
Journal:  Cureus       Date:  2021-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.